

P24615.P01

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

P24615

Total Pages

Inventor(s) or Application Identifier

Viswanathan SRINIVASAN, Ralph BROWN, David BROWN,
Himanshu PATEL, Juan Carlos MENENDEZ and
Venkatesh BALASUBRAMANIANTitle: DOSAGE FORM CONTAINING A MORPHINE
DERIVATIVE AND ANOTHER DRUG

ADDRESS TO:

Commissioner for Patents
Mail Stop Patent Application
PO Box 1450
Alexandria, VA 22313-1450

APPLICATION ELEMENTS

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
 - a. ☐ Small Entity Statement(s)
3. ☒ Specification [Total Pages 75]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 USC 113) [Total Sheets]
5. ☒ Oath or Declaration [Total Pages 3]
 - a. ☐ Newly executed (original or copy) ☒ Unexecuted
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 20 completed)
[Note Box 6 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b).
6. ☐ Incorporation By Reference (useable if Box 5b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 5b, is
considered as being part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.
7. ☐ Application Data Sheet. See 37 CFR 1.76
8. ☐ CD-Rom or CD-R in duplicate, large table or Computer
Program (Appendix)

ACCOMPANYING APPLICATION PARTS

9. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
 - c. ☐ Statements verifying identity of above copies
10. ☐ Assignment Papers (cover sheet & document(s))
11. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
12. ☐ English Translation Document (if applicable)
13. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
14. ☐ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
16. ☐ Figure of Drawing to be published
17. ☐ Foreign priority claimed
 - a. ☐ Claim of Priority
 - b. ☐ Certified Copy of Priority Document(s)
18. ☒ Nonpublication Request under 35 U.S.C. 122 (b) (2) (B) (i).
Applicant must attach form PTO/SB/35 or its equivalent.
19. ☐ Assignee: _____
20. ☒ Other: Cover Letter Filed Under 37 CFR 1.53(b) & (f)

21. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 C.F.R. 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No. _____ / _____, filed _____.
Prior application information: Examiner: _____ Group Art Unit: _____
Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.

1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191March 12, 2004
Date

Signature
Stephen M. Roylance, Reg. No. 31,296
Typed or Printed Name

P24615.P02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Viswanathan SRINIVASAN et al.

Serial No :Not Yet Assigned

Filed :Concurrently Herewith

For : DOSAGE FORM CONTAINING A MORPHINE DERIVATIVE AND ANOTHER DRUG

**COVER LETTER ACCOMPANYING U.S. PATENT APPLICATION
FILED UNDER 37 C.F.R. 1.53(b) and 1.53(f)**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Sir:

Enclosed is a new patent application for filing in the U.S. Patent and Trademark Office under 37 C.F.R. 1.53(b) and 1.53(f) in which the appropriate filing fee is not included, and the attached Declaration and Power of Attorney are in unexecuted form.

The appropriate filing fee and a properly executed Declaration and Power of Attorney will be filed within the time period set forth in the Notice to File Missing Parts of Application, unless such time period has been extended by the filing of a petition accompanied by the extension fee under the provisions of 37 C.F.R. 1.136(a).

Related to the above, this application should be associated with Customer Number 7055,
which includes the present correspondence address as follows:


GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

The above-identified application includes:

- 75 pages of specification (including Abstract);
- an unexecuted Declaration and Power of Attorney.

If there are any questions, please contact the undersigned at the below-listed telephone number.

Respectfully submitted,
Viswanathan SRINIVASAN et al.


Stephen M. Roylance
Reg. No. 31,296

March 12, 2004
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

P24615.P04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Viswanathan SRINIVASAN et al.

Serial No : Not Yet Assigned

Filed : Concurrently Herewith

For : DOSAGE FORM CONTAINING A MORPHINE DERIVATIVE AND ANOTHER
DRUG

REQUEST FOR NON-PUBLICATION UNDER 37 C.F.R. 1.213

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


Applicant hereby respectfully requests that the application not be published under 35 U.S.C. 122(b).

The undersigned hereby certifies that the invention disclosed in this application has not been and will not be the subject of an application filed in another country, or under multilateral international agreement, that requires publication at eighteen months after filing.

If any fees are required for consideration and/or entry of this non-publication request, the U.S. Patent and Trademark Office is hereby authorized to charge any additional fee, or credit any overpayment to Deposit Account No. 19-0089.

Should there be any questions, please contact the undersigned at the below listed
telephone number

Respectfully submitted,
Viswanathan SRINIVASAN et al.

A handwritten signature in black ink, appearing to read 'Stephen M. Roylance', written over a horizontal line.

Stephen M. Roylance
Reg. No. 31,296

March 12, 2004
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191